PD-1 antibody cemiplimab demonstrates 46.3% ORR in advanced cutaneous squamous cell carcinoma

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A pivotal phase II clinical study of cemiplimab, an investigational human antibody targeting PD-1, demonstrated an overall response rate of 46.3% in 82 patients with advanced cutaneous squamous cell carcinoma.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe

YOU MAY BE INTERESTED IN

Login